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ABSTRACT :   
Rationale 
Radiation therapy is widely used for cancer treatment but its efficacy is limited by 
radioresistance and by damages caused to adjacent normal tissues. Active research aims at 
maximizing tumor eradication while reducing side-effects with theranostic nanoparticles that 
act as radioenhancers in situ. Ferromagnetic materials have been identified as promising 
nanotools for image-guided radiotherapy. Here, we investigated the potential of RGD-tagged 
magnetosomes (magnetosomes@RGD), bacterial biogenic magnetic nanoparticles naturally 
coated by a biological membrane and genetically engineered to express a RGD peptide, as 
tumour enhancers to conventional radiotherapy and proton therapy. 
Methods 
The potential of native and RGD-functionalized magnetosomes to enhance the effects of 
ionizing radiations was assessed in a DNA fragmentation assay and in melanoma and colorectal 
cancer cells using in vitro clonogenic assays. The in vivo radiotherapy enhancement efficacy of 
the magnetosomes@RGD was explored in preclinical models of melanoma-bearing mice 
treated with either X-rays or protons. 
Results 
Native and RGD-tagged magnetosomes similarly enhanced radiation-induced DNA damage. 
On cancer cells, both magnetoprobes were able to boost the killing efficacy of radiotherapy, 
although to a much larger extent with the magnetosomes@RGD enhancing the mortality by 2.5 
fold in melanoma cells and by 2.9 fold in colorectal cancer cells. In vivo treatment of melanoma-
bearing mice with magnetosomes@RGD prior to X-rays led to a 65% reduction in tumor 
development compared to radiotherapy alone (31%).  Comparatively, a more effective tumor 
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growth inhibition (77%) was observed in combining RGD-decorated nanoprobes to proton 
therapy. The radioenhancing potential of magnetosomes@RGD was further evidenced by the 
DNA damage observed in the nanoscale vicinity of magnetosomes within the treated lesions. 
Conclusions 
Our results show efficacy of magnetosomes functionalized with a RGD peptide as tumor 
radioenhancers to both X-rays and protons in vivo and strengthen the interest of developing 
biogenic magnetoparticles for multimodal nanomedicine for cancer therapy.  
 
Keywords: RGD functionalized magnetosome, biogenic iron-oxide nanoparticle, radiotherapy, 
proton therapy, cancer, radiosensitization, radioenhancement, magnetotactic bacteria 
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INTRODUCTION 
Up to 50% of cancer patients receive radiotherapy (RT) at some time in their disease evolution 
(1). Although ionizing radiation dose is often needed to effectively kill tumor cells, dose 
delivery is limited by the severe damages caused to adjacent normal tissues. RT efficacy is also 
hampered by hypoxia-associated radiation resistance and other mechanisms of radioresistance 
that require that more dose be delivered to the tumor to achieve curability. Systemic 
radiosensitizing agents given concomitantly with radiation increase its local anti-tumor 
efficacy. However, such combination is associated with an increase of toxic, and sometimes 
limiting, systemic effects. With the development of nanotechnology, dose enhancement 
strategies have been proposed to improve radiation responses of tumours while minimizing 
side-effects. Very recently, such nanomedicine strategies have translated from bench to bedside 
and radioenhancing approaches are currently under investigation in a series of clinical trials 
(2,3). 
To be an efficient radio-enhancer, the nano-object has to contain high-Z elements such as gold, 
gadolinium, platinum, iron, which under irradiation will generate secondary radiation and 
electrons at the subcellular scale. Radiation enhancement by scattered photons, photoelectrons, 
Compton and Auger electrons, etc (4,5) thus occurs by an increase of the dose deposited locally. 
Radiopaque radiation-effect enhancing nanoparticles can be used to image drug biodistribution 
in tissues (6). One drawback of such agents resides in their limited spatial selectivity. Among 
radiation-effect enhancing nanoparticles, iron oxide materials combine unique physicochemical 
(magnetic) properties for safe real-time MRI imaging and highly effective radioenhancement 
(7-9). However, passive targeting is available for certain tumours only and does not necessarily 
guarantee internalization of radiation-effect enhancing nanoparticles by targeted cells. Thus, 
iron-oxide based nano-objects have to be modified with suitable targeting ligands, such as small 
organic molecules, peptides, proteins, antibodies, and aptamers, to enable active cell targeting. 
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This has been done with variable success (10,11) due to the lack of solubility of iron-oxide 
nanoprobes in biological fluids. Indeed, modifications of surface characteristics are required to 
provide high dispersion stability (12). Moreover, coating strategies are still limited by the 
complex surface chemistry of the nano-probes, by relatively low receptor density on tumors 
and by homotypic and heterotypic binding properties of membrane receptors on cancer cells.  
The use of magnetosomes, biomineralized iron-oxide nanoparticles naturally coated by a 
biological membrane and purified magnetotactic bacteria, represents a promising alternative to 
overcome both the problem of coating and solubility. Magnetosomes have been shown to be 
safe and efficient in vivo MRI probes in mouse brain angiograms (13). Such biogenic particles 
can be genetically functionalized with peptides or proteins to confer even better selectivity to 
the probe (14,15). In this context, we previously demonstrated the feasibility of using 
genetically tailored magnetosomes to express a RGD peptide (rich in Arginine, Glycine, and 
Aspartic residues) recognized by several members of the superfamily of integrins present on 
tumor cells and involved in cancer progression (18,19). These functionalyzed bionanoparticles 
called magnetosome@RGD actively target tumor cells and blood vessels and provide unique 
MRI probes in brain tumour models (13,16).  In addition, a therapeutic effect has been 
demonstrated by hyperthermia magnetic treatment (17,18), photothermal therapy (19-21), and 
drug delivery systems (22).  
 
In the present study, we explored the possibility to enhance radiotherapy by using single-step 
produced-magnetosomes, decorated with the yellow fluorescent protein Venus and a RGD 
motif (magnetosomes@RGD) or with the yellow fluorescent protein Venus alone 
(magnetosome). We assumed that the RGD peptide would facilitate the cellular uptake of the 
magnetosomes, thereby increasing the dose deposited in situ. The potential of both forms of 
biogenic magnetic radiation-effect enhancing nanoparticles to increase ionizing radiation 
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effects was first analyzed on DNA and on two cellular models, namely colorectal cancer cells 
and melanoma cells known for their relative radioresistance (23) (24). We next evaluated the 
in vivo radioenhancing potential of magnetosomes@RGD after injection into mouse melanoma 
xenografts irradiated with photons. For radioresistant tumors  surrounded by sensitive tissues, 
proton therapy presents a dose distribution superiority compared to other RT modalities with 
photons, by avoiding damage to the tissues behind the tumor. However, damages caused in 
front of the tumor may still remain significant and strategies to reduce radiation doses are 
needed. Therefore, we further explored the therapeutic efficacy of magnetosomes combined to 
protons. To the best of our knowledge, this study is the first to report the use of biogenic 
magnetic radiation-effect enhancing nanoparticles decorated with an RGD peptide as tumor 
radioenhancers to both X-rays and protons.  
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MATERIALS AND METHODS 
Culture of magnetotactic bacteria and magnetosomes production 
The bionanoparticules, magnetosomes@RGD and magnetosomes were prepared as described 
in Plan et al (23). Briefly, the AMB1 strain were genetically modified to biosynthetized 
magnetosomes@RGD and magnetosomes(Fig Supp1A). The RGD peptide was used or not to 
decorate the magnetosome membrane in fusion with the yellow fluorescent protein venus and 
the magnetosome membrane anchor mamC (Fig Supp 1B). Western Blot experiments 
confirmed the insertion of MamC-Venus or MamC-Venus-RGD at the magnetosomal 
membrane using Anti-venus antibodies (Fig Supp 1C) . Each batch of magnetosomes was 
systematically checked for structure by transmission electron microscopy (Fig Supp 1A) and 
size by Nanoparticle Tracking Analysis (Fig Supp 1B). Both genetically modified AMB-1 
strains were grown in 7L bioreactor and cells from late exponential-phase culture were 
harvested by centrifugation (7500 g, 10 min, 4°C). The pellet (≈19 g per 6L) was resuspended 
in 100 ml of purification buffer 1 (20 mM HEPES, 1mM EDTA, 0.9% NaCl, 8% glycerol, pH 
7,5 in presence of a cocktail of anti protéase). The cells were then disrupted 3 times with a 
French press (1000 PSI, 4°C). The tubes were left for 30 min at 4°C in contact of a magnet 
(MACSi-MAGtm separator, Miltennyi Biotec), resulting in magnetosomes collection. The 
unretained fraction was removed and the magnetosome fraction was resuspended in 45 ml of 
buffer. This magnetic purification step was performed 5 times with buffer 1 (without anti 
protease) then 5 times with buffer 2 (20 mM HEPES, 0.9% NaCl, 8% glycerol, pH 7,5). After 
the washing steps, the magnetosomes were resuspended in buffer 3 (20 mM HEPES, 8% 
glycerol, pH 7,5), at a concentration of 3 g/l of iron (ICP-AES measurement) and 100 μL 
aliquots were flash-frozen in liquid nitrogen then stored at −80 °C.  
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Magnetite magnetosomes were biosynthetized under strict genetic control in Magnetospirillum 
magneticum strain AMB-1 (ATCC700264) (Fig Supp1A). As described in Boucher et al (16), 
the Venus fluorescent reporter was  inserted in the lipid membrane by genetic manipulation. 
This first class of biomagnetite is simply referred to as "magnetosomes". The exact same genetic 
construct was used for "magnetosomes@RGD", except that, in addition to the Venus reporter, 
the RGD peptide was used to decorate the magnetosome membrane (Fig Supp 1B). The size of 
both types of particles are similar but western Blot experiments confirmed the insertion of 
MamC-Venus or MamC-Venus-RGD at the magnetosomal membrane using Anti-venus 
antibodies (Fig Supp 1C)  . Both genetically modified AMB-1 strains were grown in 7L 
bioreactor and the same procedure was used for both strains to purify the magnetosomes. 
Briefly, cells from late exponential-phase culture were harvested by centrifugation (7500 g, 10 
min, 4°C). The pellet (≈19 g per 6L) was resuspended in 100 ml of purification buffer 1 (20 
mM HEPES, 1mM EDTA, 0.9% NaCl, 8% glycerol, pH 7,5 in presence of a cocktail of anti 
protéase). The cells were then disrupted 3 times with a French press (1000 PSI, 4°C). The tubes 
were left for 30 min at 4°C in contact of a magnet (MACSi-MAGtm separator, Miltennyi 
Biotec), resulting in magnetosomes collection. The unretained fraction was removed and the 
magnetosome fraction was resuspended in 45 ml of buffer. This magnetic purification step was 
performed 5 times with buffer 1 (without anti protease) then 5 times with buffer 2 (20 mM 
HEPES, 0.9% NaCl, 8% glycerol, pH 7,5). After the washing steps, the magnetosomes were 
resuspended in buffer 3 (20 mM HEPES, 8% glycerol, pH 7,5), at a concentration of 3 g/l of 
iron (ICP-AES measurement) and 100 μL aliquots were flash-frozen in liquid nitrogen then 
stored at −80 °C. Each batch of magnetosomes was systematically checked for structure by 
transmission electron microscopy (Fig Supp 1D).  10 µl drops were deposited on grids, 
evaporated, and observed with a Phillips Tecnai 12 electron microscope. The images were 
processed with Fiji software to determine the magnetosome diameter. 
Code de champ modifié
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DNA preparation and radiation-induced damage quantification  
pGEM-3Zf(−) plasmid DNA (3197 bp, Promega) was extracted from E. coli DH5α and purified 
with the QIAfilter Plasmid Giga Kit (Qiagen). The DNA pellet was redissolved in TE buffer 
(10 mM Tris, 1 mM EDTA, pH 8) and DNA concentration was obtained by measuring its 
absorption at 260 nm. Solutions of DNA (100 ng) and of magnetosomes@RGD or 
magnetosomes (0-500 nM) were mixed just before X-rays exposure (0, 0.5, 1, 2, 3 or 5 Gy) 
(RX Optitop 150/40/80 HC, Siemens). DNA damages were quantified by agarose gel 
electrophoresis stained with SYBR® Gold (Invitrogen). The gels were imaged with a 
Luminescent Image Analyzer LAS 3000 system. Resulting images were analyzed using ImageJ 
software to determine the relative amounts of supercoiled, circular and linear DNA forms  (25). 
Cell culture 
The B16F10 melanoma and the DHD/K12/TRb (PROb) colorectal cancer cells were cultured 
in DMEM (GIBCO, France) supplemented with 10 % heat-inactivated fetal calf serum (FCS, 
GIBCO) at 37 °C under a humidified atmosphere containing 5 % CO2. Cells were passaged by 
using 0.05 % trypsin.  
In vitro measurement of magnetosomes toxicity 
Five hundred DHD or B16F10 cells were plated in 96-well.  After 24 h, the culture medium 
was replaced with 100 L of fresh medium or medium containing magnetosomes@RGD or 
magnetosomes at the indicated concentrations and incubated for 2 hours at 37 °C. After 3 
washes with 1× PBS (pH 7.4), the treated cells were incubated for 4 days in complete medium. 
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Cell viability was assessed by the MTT assay using a spectrophotometer Multiskan GO 
microplate (Thermo Scientific).  
Clonogenic cell survival assay 
The radioenhanced cell kill efficacy of magnetosomes@RGD or magnetosomes to DHD and to 
B16F10 cells was assessed by the clonogenic assay. Different number of cells (50, 100, 300, 
1000) were plated in 12-well.  After 24 h, the culture medium was replaced with 1 mL of fresh 
medium or medium containing magnetosomes@RGD or magnetosomes at the indicated 
concentrations and incubated for 2 hours at 37 °C. After 3 washes with 1× PBS (pH 7.4), the 
treated cells were exposed to 0, 0.25, 0.5, 0.75, 1, 2 or 3 Gy of X rays (RX Optitop 150/40/80 
HC, Siemens) before being incubated for 9–14 days. The colonies were fixed with methanol 
and stained with 0.4 % crystal violet. Finally, the plates were inspected by microscopy and the 
number of the colonies was counted. Each assay was made in triplicate and only colonies 
containing at least 50 cells were counted.  
 
Mice  
Eight-week-old Balb/c female athymic (nude) mice were obtained from Janvier (Le Genest 
Saint Isle, France). Animal housing and procedures were conducted according to French 
Agriculture Ministry guidelines and were approved by the local ethics committee.  
Xenografts and treatments 
Briefly, each mouse was subcutaneously injected with 5×105 B16F10 cells in the flank. An 
apparently visible tumor mass was observed 6 days after injection. At day 8, when the tumor 
size was about 100 mm3, the mice were randomly divided into three groups: control group 
(saline only), irradiation group (X rays or protons), magnetosomes@RGD/ irradiation group. 
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Five mice were included in each group. On day 8, mice treated with magnetosomes received 
either an intratumor injection (750 nmol) or an intravenous injection (4 mol) of 
magnetosomes@RGD. On day 9, mice subjected to irradiation were exposed to 5 Gy of X rays 
or protons. Mice were monitored after treatments. The longest (a) and shortest (b) tumor 
diameters (mm) were recorded and formula for an ellipsoid sphere (0.52×a×b2) was utilized to 
determine the volume of tumor. Tumors were preserved in liquid nitrogen for future studies.  
Irradiation modalities  
For the in vitro study (cells and DNA), we used the OPTITOP 150/40/80 HC x-ray tube 
(SIEMENS) belonging to a medical imaging table. For the in vivo study, mice were 
anesthetized and placed horizontally into a 43855F-CP160 Faxitron x-ray device (EDIMEX). 
To generate the same damages on cells and on mice, we adjusted the beam quality so that it be 
the same on both tubes: 99 kV High Voltage and 3,7 mmAl half value layer. To reach this half 
value layer on the faxitron’s tube, we introduced a 3 mm Al aluminium filter beyond the exit 
window. 
For in vivo proton therapy experiements, mice were anesthetized and placed vertically on a 
robotic chair device. Proton therapy was performed using a single scattering beam line device 
with beam energy modulation (using a range shifter and a rotating wheel placed in the beam 
line) in depth and beam conformation laterally using a brass collimator at the beam end. Tumors 
were placed within the flat portion of the modulated Bragg peak, where relative biological 
efficacy (RBE) of protons compared to photons is 1.1. The distal fall off, where RBE may 
exceed 1.1, was over the deeper part of the tumor. The dose with protons is reported in Gy RBE.  
 
Histology/Fluorescence Images processing 
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Formalin-fixed, paraffin-embedded tumour sections were stained with hematoxylin/eosin for 
morphologic evaluation. The sections were stained with DAPI (4′,6-diamidino-2-phenylindole) 
to visualize nuclei integrity (excitation wavelengths of 405 nm and emission wavelengths of 
471 nm) and venus (YFP)-labelled magnetosomes were detected in green (excitation 
wavelengths of 514 nm and emission wavelengths of 542 nm). The image of Fluorescence 
microscopy images were acquired with a Zeiss LSM 780 microscope at ×63 magnification for 
single field-of-view focusing on structures of interest inside the tumor. 
 
Statistical analysis 
Statistical analysis was performed using Prism (GraphPad software). Dual comparisons were 
made using a Student’s t-test and comparisons between multiple conditions were analyzed using 
ANOVA. Statistical significance was set at P < 0.05.  
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RESULTS 
DNA damage radioenhancement by magnetosomes  
Magnetosomes@RGD and magnetosomes were prepared and characterized as described in Plan 
et al. (19). In order to investigate their radioenhancing effect, DNA plasmids were subjected to 
X rays in the presence and in the absence of both types of magnetosomes. The different forms 
of plasmid DNA were resolved by a 1% agarose gel electrophoresis and quantified with ImageJ 
software (26). Upon irradiation, the supercoiled plasmid (SC) undergoes a single-strand break 
(SSB) causing the molecule to adopt a circular form (CF). The native supercoiled form decrease 
was quantified as a function of the irradiation dose. A typical electrophoresis gel showing DNA 
damage after exposure to 1, 2 and to 3 Gy is presented in Figure 1A. Non-irradiated samples 
mainly consisted of supercoiled DNA (SC) whereas the circular form accounted for ∼5%. After 
irradiation with doses as low as 2 Gy, the proportion of the supercoiled DNA was significantly 
diminished, mainly in favour of the circular form. However, 1 Gy irradiation only led to a minor 
change in the proportions of the SC and the CF forms, thus suggesting minor DNA damage at 
such dose. Therefore, the dose of 1 Gy was retained to further study the radioenhancing 
potential of magnetosomes. Admixing DNA with increasing concentrations of magnetosomes 
(5, 50 and 500 nM) led to enhanced DNA damage in response to 1 Gy X-rays, as indicated by 
the SC decrease concomitant with the CF increase (Figure 1B, C and D). This radioenhancing 
effect on DNA in the presence of magnetosomes was observed with an enhancement factor of 
2.1 ± 0.3 with 50 nM (p<0.05), and of 3.2 ± 0.9 (p<0.05) with 500 nM magnetosomes , but 
remained negligible with 5 nM. Accordingly, a significant increase in the circular form was 
measured with 50 nM (and with 500 nM (Fig. 2D). These results mean that in the presence of 
magnetosomes, only 50% and 30% of the radiation dose, respectively, is necessary to induce 
an equivalent damage. Similar results were obtained with magnetosomes@RGD, thus 
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suggesting the absence of a significant impact of the RGD functionalization on the DNA radio-
enhancement potential of the particles (data not shown). 
 
Radioenhancing potential of magnetosomes on B16-F10 and DHD cells 
Studies were carried out with the B16F10 (melanoma) and the DHD/K12/TRb (colorectal cancer) 
cells to determine the cytotoxicity of magnetosomes and magnetosomes@RGD in viability 
assays (Figure 2A and B). The fraction of the viable cells was determined after exposure of the 
cells for 2 hours to several doses of magnetosomes, ranging from 100 M to 1 mM, followed 
by cell culture for 5 days. No significant reduction in cell viability was observed after exposure 
of both cell types to concentrations reaching even up to 1 mM.  
In order to determine whether magnetosomes and magnetosomes@RGD could radioenhance 
damages in melanoma and colorectal cancer cells irradiated with X-rays, the respective 
sensitivities of both cell lines to radiation were assessed in clonogenic assays. As shown on 
Figures 2C and D, the LD50 (Lethal dose causing the death of 50% of cells) was obtained with 
1.2 Gy in B16-F10 cells and with 0.8 Gy in DHD cells, thus indicating a lower sensitivity to 
radiation of the melanoma cell line to X-rays compared to the colorectal cancer cells. Radiation 
doses leading to approximately 20-25 % of mortality in both cell types were then chosen to 
assess the potential enhancement factor of magnetosomes, precisely 0.75 Gy for B16F10 cells 
and 0.25 Gy for DHD cells. The effect of pretreating the cells for 2 hours with 200 M 
magnetosomes or magnetosomes@RGD before irradiation was tested. Figures 2E and 2F show 
in both cells types a moderate enhancement factor with magnetosomes/ X-rays compared to X-
rays alone. Interestingly, this enhancing effect was much more pronounced with the 
functionalized magnetoparticles. Indeed, magnetosomes@RGD could reduce the cell survival 
fraction from 81% to 50% for the B16F10 cells (Figure 2E) and from 75% to 28% for the DHD 
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cells (Figure 2F), thus suggesting the ability of the membrane-anchored RGD motif to promote 
the binding and the internalization of the magnetoparticles by both targeted cells.  
Assessment of radioenhancing potential of magnetosomes@RGD in vivo 
Cellular damage radioenhancement observed here for magnetosomes@RGD together with their 
high efficient internalization previously observed in tumor cells (18-21) prompted us to 
investigate their radioenhancing potential in a tumour xenograft model. The B16 xenograft 
model was chosen based on the observation that the B16-F10 melanoma cells proved to be more 
resistant against radiation in vitro than the colorectal DHD cells. B16 tumours were generated on the 
flank of Balb/c mice and allowed to grow for one week. At day 8 post-induction with melanoma 
cells, mice developed tumours with an average volume of 50 mm3, at which point, animals were 
randomly assigned to one of 2 treatment groups: saline (control) or magnetosomes@RGD, 
delivered by 3 intratumoral injections. At day 9, half of the tumors in the saline- and in the 
magnetosome-treated groups were administered a single dose of 5 Gy X-rays. Tumor 
progression was then measured over time and compared between the four groups: saline, 
magnetosomes@RGD, X-rays, magnetosomes@RGD/ X-rays.  
Figure 3A shows that control xenografts grew up to approximately 600 mm3 within 17 days 
after implantation. Histologic analysis of the tumours shows highly proliferative cancer cells 
(Figure 4A). Treatment with magnetosomes@RGD alone had minimal impact on tumour 
growth and the tumour mass failed to show any remarkable change compared to the untreated 
group. The 5Gy X-rays treatment by day 9 significantly impaired tumor progression resulting 
in a 29% reduction in the tumor volume by day 17 (425 mm3 in the X ray group vs 620 mm3, 
in the control group, p= 0.03). In agreement with the radioenhancing effects observed in vitro, 
the combination of magnetosomes / 5Gy X-rays attenuated tumor growth by nearly 50% over 
radiation alone (217 mm3 in the magnetosomes@RGD /X-ray group vs 425 mm3 in the X-ray 
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group, p=0.039), leading to an overall 65% decrease in lesion size compared to control 
xenografts. The most remarkable observation on the lesions treated with magnetosomes@RGD/ 
X-rays was the presence of large areas of necrosis that extended deep into the core of the 
tumours, whereas 5-Gy irradiated tumors rarely demonstrated necrosis at necropsy (Figure 4C 
and D).  
Upon observation of the radioenhancing effects of combining RGD-functionalized 
magnetoparticles with X-rays, we next explored the ability of the nanomaterial to enhance the 
radiation effect of proton therapy using the same melanoma xenograft model. As shown on 
Figure 3B, a single 5 Gy RBE irradiation with protons led to a 37% reduction in tumor growth 
by day 17 (392 mm3 in the proton group vs 620 mm3, in the control group, p= 0.027). However, 
this reduction was not statistically significant compared to that induced by 5 Gy X-rays. Tumour 
development was further decreased by 40% when combined treatments magnetosomes@RGD/ 
protons were administered to mice (Figure 3B), thus leading to lesions 77% smaller than the 
untreated xenografts (139 mm3 in the magnetosomes@RGD / protons group vs 620 mm3, in the 
control group, p= 0.008). This enhancement effect of the magnetosomes upon proton therapy 
was significantly superior when measured by day 17 compared to that measured upon X-rays 
(p=0.04) and consistently correlated with the extent of histologic tumor necrosis post-
irradiation in the treated lesions (Figure 4F).  
We next studied whether the occurrence of necrosis was associated with the presence of 
magnetosomes@RGD within melanoma biopsies isolated at necropsy. Necrosis reflected by 
the loss of DNA integrity within the tumour cells was visualized by DAPI staining revealing 
cell nuclei in blue. The localization of magnetosomes@RGD within melanoma tumours was 
assessed by confocal immunofluorescence analysis of the green Venus protein (Figure 5). As 
expected, control melanoma biopsies exhibited intact nuclei (Figure 5A), whereas irradiated 
lesions showed partially altered DNA integrity within nuclei (Figure 5B). Enrichment of lesions 
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with magnetosomes@RGD led to marked DNA fragmentation reflecting the histologic necrosis 
observed in the treated tumours on the trans images (Figure 5C). Such necrotic patterns were 
associated with the presence of numerous Venus-labelled-magnetoparticles. Interestingly, the 
magnetosomes@RGD were still detectable at necropsy 9 days after injection into tumours. 
Altogether, these data suggest that the accumulated magnetosomes@RGD in the tumour region 
significantly boosted the efficacy of radiotherapy and delayed tumour growth.  
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DISCUSSION 
Magnetic nanoparticles can induce enhanced radiation effects and can be functionalized (7-9) 
by adding a coating shell on their surface. Specific shell coating stabilizes the nanoparticles and 
favors interactions with biological systems, while protecting the surrounding environnment 
from radiation-induced oxidation. However, synthesis of functional groups to accommodate 
may be complex. An alternative approach to the complex conventional synthetic routes is to 
exploit the controlled formation of stable and well-ordered solid inorganic coumpounds by 
biological systems, such as magnetotactic bacteria. Recently, several studies including those 
from our group have demonstrated the great properties of magnetosomes, biogenic 
magnetoparticles naturally coated by a biological membrane, for various biomedical 
applications. Thanks to their bio-magnetic properties, the magnetosome diagnostic potential 
have been revealed in MRI field (13) (16) and a therapeutic effect has been demonstrated by 
hyperthermia magnetic treatment (17,18), photothermal therapy (19-21), and drug delivery 
systems (22).  
In the present study, we explored the radiation enhancement potential of magnetosomes 
genetically modified to express RGD motifs capable of actively targeting tumor cells and 
angiogenic blood vessels. Our in vitro data show that native magnetosomes and 
magnetosomes@RGD are equally efficient to promote the damaging action of X-rays directly 
on DNA. On cancer cells however, cellular damage radioenhancement observed for 
magnetosomes@RGD was greater than that of unlabeled particles. Our quantitative measures 
revealed that magnetosomes@RGD could increase the mortality by 2.5 fold in melanoma cells 
and by 2.9 fold in colorectal cancer cells, with irradiating doses set at 0.75 and at 0.25 Gy, 
respectively. The fact that lower mortality is obtained in melanoma cells despite the use of 
higher radiation doses compared to colorectal cancer cells is consistent with the higher 
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radioresistance of the melanoma cells. Of note, a short incubation time of the cancer cells with 
both types of magnetosomes was deliberately chosen in order to clearly assess the potential 
impact of the RGD functionalization at the magnetosome surface on the cellular uptake. This 
result is in accordance with our previous observations showing that internalization of control 
magnetosomes on cancer cells is not optimal within 2 hours and can be markedly increased by 
lengthening the incubation time up to 24 hours (16). However, the RGD-mediated high efficient 
internalization of magnetoparticles previously observed by our group in tumor cells still 
remained despite longer incubation times.  In terms of mechanism, DNA damage is commonly 
considered as the cause of radiation-induced cell death (27,28). Consistently, nanoparticles have 
been proposed to enhance ionizing radiation effects through an amplification of this DNA 
damage. However, many in vitro studies indicated that the radiation-effect enhancing 
nanoparticles located in the cell cytosplasm also seem to amplify cell killing without entering 
the nucleus (29-34), simply by generating electron showers capable of spreading as far as 
several micrometers (35).  
Encouraged by the in vitro performance of magnetosomes@RGD with X-rays, we further 
explored the potential of the combined therapy in B16 xenografts. As a monotherapy 
administered on day 9 after tumor implantation into mice, 5 Gy X-rays were able to reduce 
tumor growth by 29 %, indicating the tumor-inhibiting efficacy of radiation. The enrichment 
of tumours with magnetosomes@RGD prior to radiotherapy led to a much more effective 
tumor growth inhibition compared to radiation alone, lesions being reduced by 65 % in volume. 
In addition, the treated lesions featured much larger necrotic areas colocalizing with the 
accumulated magnetoparticles thus confirming the ability of RGD-decorated magnetosomes to 
boost the killing efficacy of ionizing radiations. Interestingly, we observed that the 
magnetosomes@RGD were still detectable at necropsy 9 days after injection. Considering that 
the 65% reduction in tumor size was obtained after a single irradiation,  it is tempting to 
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speculate that much more impressive tumour inhibition could be observed with repeated X-ray 
treatments.  
Beyond conventional radiotherapy, nanomedicine have also been envisaged to optimize proton 
therapy. Indeed, targeting tumours with protons enables to spare healthy tissue sited behind the 
tumour region due to the physical superiority of protons represented by their abrupt energy loss 
and finite dose deposition at the end of their predefined range. However, the radiation dose 
received by tissues in front of the tumor still needs to be reduced, especially when tumors are 
adjacent to critical structures such as in brain or head and neck tumours. Based on the 
convincing results obtained when combining magnetosomes@RGD to X-rays, we further 
investigated the ability of magnetoparticles to amplify the killing efficacy of protons using the 
similar melanoma model. Although, 5 Gy RBE protons similarly reduced tumor growth 
compared to 5 Gy X-rays, melanoma tumours appeared clearly smaller with the magnetosome-
proton therapy compared to the same combination with X-rays. These data suggest a higher 
radioenhancing potential of the magnetosomes upon irradiation with protons rather than 
photons. In addition to the 1.1 radiobiological efficacy of protons compared to photons, such 
differences might be explained by different nuclear reactions of the magnetite crystal under 
distinct radiations types. Naturally occurring iron (26Fe) consists of four stable isotopes, among 
which 56Fe accounts for 91%. Whereas excitation of 56F by photons follows a (p, n) reaction, 
protons can produce a 56Fe(p,2n)55Co reaction generating twice more secondary electrons 
compared to X rays, and therefore potentially more damaging effects within cells (36).  Such 
hypothesis is consistent with the enhanced extent of necrosis visualized within 
magnetosomes@RGD-treated melanoma tumors irradiated with protons compared to photons.   
 
 
In conclusion, our work provides the first evidence of the radioenhancing potential of 
magnetosomes@RGD in conventional radiotherapy and proton therapy and pave the way 
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to  promising investigations using systemic administration of the particles. The combined 
features including simple preparation, good biocompatibility, active cancer cell targeting 
property, strong radioenhancing effect and potential PET imaging capability under proton 
therapy strengthen the interest of developing biogenic magnetoparticles for multimodal 
nanomedicine for cancer therapy.  
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FIGURE LEGENDS  
Figure 1: DNA damage radioenhanced by magnetosomes and magnetosomes@RGD. (A) 
Typical agarose gel electrophoresis showing DNA damage after exposure to 1, 2 and to 3 Gy 
X rays. Non-irradiated DNA mainly consists of supercoiled DNA (SC). Upon irradiation, the 
supercoiled plasmid (SC) undergoes a single-strand break (SSB) causing the molecule to adopt 
a circular form (CF). MM: Mass marker. (B) Influence of the magnetosome concentration on 
the loss of the native supercoiled DNA induced by 1Gy X-rays. Representative electrophoresis 
gels showing the loss of the SC form and the increase in the CF form of DNA irradiated in the 
presence of increasing concentrations of magnetosomes (upper panel) or magnetosomes@RGD 
(lower panel). Quantification of the loss of native supercoiled DNA (C) and of the increase in 
the circular form DNA (D) versus magnetosomes concentrations. The data presented are the 
mean ± SEM of triplicates and are representative of three independent experiments.  * p < 0.05; 
** p < 0.01. 
Figure 2: Radioenhancement potential of magnetosomes and magnetosomes@RGD on 
B16F10 melanoma and DHD colorectal carcinoma cells. Cytotoxicity assays of B16F10 (A) 
and DHD (B) cells in the presence of increasing concentrations of magnetosomes or 
magnetosomes@RGD. Cell survival rate of B16F10 (C) and DHD (D) cells irradiated by X-
rays at the indicated doses. Cell viability of B16F10 (E) and DHD (F) cells assessed in 
clonogenic assays on cancer cells pretreated for 2 hours with 200 M magnetosomes or 
magnetosomes@RGD prior to X-rays at the indicated dose. The data presented are the mean ± 
SEM of triplicates and are representative of three independent experiments.  * p < 0.05; ** p < 
0.01. 
Figure 3: Assessment of radioenhancing potential of magnetosomes@RGD in vivo. 
Melanoma xenograft-bearing mice were subjected to (A) X-rays (5 Gy) or (B) protons (5 Gy). 
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Tumor development was monitored over time in mice untreated (filled circles) or treated with 
either magnetosomes@RGD alone (open cirles), or with 5 Gy X rays (filled squares), or with a 
combination of magnetosomes@RGD / X rays (filled triangles), with 5 Gy protons (open 
squares), or with a combination of magnetosomes@RGD / protons (open triangles). (n = 5 mice 
per condition). * p < 0.05; ** p < 0.01.  
Figure 4: Histology of B16 tumors after treatment with radiotherapy combined or not 
with magnetosomes@RGD. Tumor histology was compared on sections (10X magnification) 
of lesions from B16-challenged mice either untreated (A, C, E), or treated with RGD-V-AMB1 
magnetosomes (B, D, F) before receiving radiotherapy with X-rays (C, D) or with protons (E, 
F). N = area of necrosis in a liver tumor.  
Figure 5: Fluorescent analyses of B16 tumors after treatment with radiotherapy combined 
or not with magnetosomes@RGD. Confocal microscopy on untreated (A), X-rays treated (B) 
or magnetosome@RDG injection and X-rays treated (C) tumors sections. The nuclei were 
visualized in blue after DAPI staining and the magnetosome@RGD were detectable in yellow 
tanks to the venus protein.  Transmision acquisition with nucleus staining and 
magnetosomes@RGD are shown in the overlay images. 
Figure S1: Synthesis and characterization of magnetosomes. (A) Representative TEM 
image of Magnetospirulum magneticum (AMB-1) and isolated magnetosomes. (B) Size 
distribution of magnetosomes suspension performed using Nanoparticle Tracking Analyse 
(NTA), indicating for both magnetosome@RGD (upper panel) and magnetosomes (bottom 
panel) a crystal size of 50 nm surrounded by a bilipidic bilayer of 2X 12nm. (C) The correct 
functionalization was verified by (a) SDS-PAGE gel (10% acrylamide) with 5 µg of 
magnetosomal proteins per lane stained with Coomassie blue (lane 1: Magnetosomes@RGD 
43.7 kDa, lane 2: Magnetosomes 42.5 kDa), and (b) Western blot with 1µg of magnetosomal 
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protein per lane probed with Living Colors® A.v. Monoclonal Antibody (JL-8) against venus 
protein (lane 1:Magnetosomes@RGD 43.7 kDa, lane 2: Magnetosomes 42.5 kDa). 
 
 
  
25 
 
Abbreviations 
RT 
MTS 
RGD: rich in Arginine, Glycine, and Aspartic residues  
MRI: 
AMB1: 
MTT: 
SYBR: 
AND: 
Gy: 
DAPI: 
YFP  
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